Valiant Laboratories Limited (NSE:VALIANTLAB)

India · Delayed Price · Currency is INR

128.40

+0.07 (0.05%)

Oct 30, 2026, 3:14 PM IST

Market Cap	6.97B +51.7%
Revenue (ttm)	3.06B +89.6%
Net Income	160.14M +12,314.1%
EPS	2.95 +9,817.7%
Shares Out	54.31M
PE Ratio	43.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,704
Open	130.88
Previous Close	128.33
Day's Range	128.33 - 130.88
52-Week Range	49.51 - 141.38
Beta	0.92
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Valiant Laboratories

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also manufactures and sells specialty chemicals and chemical intermediates, including chlorophenol derivatives, benzene-based specialty chemicals and other chemical intermediates to agroche... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1980

Employees 84

Stock Exchange National Stock Exchange of India

Ticker Symbol VALIANTLAB

Full Company Profile

Financial Performance

In fiscal year 2026, Valiant Laboratories's revenue was 2.37 billion, an increase of 78.04% compared to the previous year's 1.33 billion. Losses were -32.68 million, 48.5% more than in 2025.

Financial Statements